Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
IMD-1828 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
IMD-1828: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
DFI-105 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
DFI-105: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Anti CD 19/22 CAR- T Cells(Medical Visual Systems) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
Anti CD 19/22 CAR- T Cells(Medical Visual Systems): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
8 min read
GVB-2001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
GVB-2001: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Follicular stem cells(The National Academy of Sciences of Belarus) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
Follicular stem cells(The National Academy of Sciences of Belarus): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.
8 min read
BMS-986449 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
BMS-986449: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
QY211 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
QY211: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
INP-12 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
INP-12: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ALN-APOC3 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
ALN-APOC3: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CPK-850 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
CPK-850: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
68Ga-PSMA-CYC Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
68Ga-PSMA-CYC: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
TAK-505 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
TAK-505: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.